Non-Small Cell Lung Carcinoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the Kras gene are specific for adenocarcinoma, a subclass of non small cell lung cancer (NSCLC).
|
2547647 |
1989 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study investigates the prevalence of K-ras mutation in autopsy tumors with NSCLC, and the correlation of K-ras gene point mutations between primary tumors and metastases in NSCLC.
|
8081702 |
1994 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
|
8553077 |
1995 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We have previously demonstrated a strong association between K-ras gene mutations, as determined by PCR followed by allele-specific oligonucleotide hybridization (ASO-h), and survival in non-small cell lung cancer patients.
|
9816271 |
1996 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for a mutation of the p53 gene occurring in exons 5-8.
|
9099959 |
1997 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
|
9472092 |
1998 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of epidermal growth factor receptor (EGF-R), K-ras gene mutations and c-myc gene amplification were studied in tumor and normal lung tissues from 100 patients with non-small cell lung cancer.
|
9468555 |
1998 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Because there is no clear consensus as to the predictive value of K-ras gene mutation for survival in patients with lung cancer, we examined the occurrence of K-ras mutations in a large, prospective case series of non-small-cell lung cancer (NSCLC).
|
10580029 |
1999 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dominant oncogenes of the Myc family are frequently overexpressed in both SCLC and non-small cell lung cancer (NSCLC), while the K-RAS oncogene is never mutated in SCLC but it is in 30% of NSCLCs.
|
11479891 |
2001 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
K-ras gene mutations in non-small cell lung cancer in Japanese.
|
11410804 |
2001 |
Non-Small Cell Lung Carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that the wild-type KRAS allele is occasionally lost in human lung cancer, and that the oncogenic activation of mutant KRAS is more frequently associated with an overexpression of the mutant allele than with a loss of the wild-type allele in human NSCLC development.
|
14601056 |
2003 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.
|
12606951 |
2003 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results showed that the majority of the primary NSCLCs with Kras2 mutations lack RASSF1A inactivation, and both RASSF1A inactivation and Kras2 mutation events occur frequently in adenocarcinomas and large cell carcinomas.
|
14511407 |
2004 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
|
15112277 |
2004 |
Non-Small Cell Lung Carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
|
15842656 |
2005 |
Non-Small Cell Lung Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The implications of EGFR mutations in patients treated with EGFR inhibitors plus first-line chemotherapy are unknown.KRAS is frequently activated in NSCLC.
|
16043828 |
2005 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The combined HR was 1.35 (95% CI: 1.16-1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26-2.02) and in studies using PCR (HR 1.40; 95% CI 1.18-1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86-1.34).
|
15597105 |
2005 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the K-ras gene are found in a subset of non-small- cell lung carcinomas (NSCLC).
|
15875089 |
2005 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overall, we detected 30 EGFR mutations (19.6%) and 6 K-RAS mutations (3.9%) in the 153 NSCLCs.
|
15815931 |
2005 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS gene mutations were present in 50 (8%) of the 617 NSCLCs but not in any tumors with an EGFR TK domain mutation.
|
15741570 |
2005 |
Non-Small Cell Lung Carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
Non-Small Cell Lung Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Mutations in the epidermal growth factor receptor gene (EGFR), HER-2, and KRAS and the methylation profile of 9 genes for NSCLC were analyzed and correlated with clinical and histologic data.
|
16598760 |
2006 |
Non-Small Cell Lung Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Treatment with MZ-J-7-138 or JV-1-92 inhibited orthotopic growth of H460 NSCLC by 52-65% (P < 0.001) and was associated with a significant decrease in protein expression of K-Ras, cyclooxygenase-2 (Cox-2) and phospho-Akt (pAkt).
|
16983095 |
2006 |